Objecfive To investigate the relationship between single nucleotide polymorphism-56(SNP-56)in calpain-10(CAPN-10)gene and polycystic ovary syndrome(PCOS)in Chinese.Methods The genotypes of SNP-56 of CAPN-10 were determined through polymerase chain reaction Tm-shift genotyping method in 638 local women in Shandong Province.Among them,334 were patients with PCOS (PCOS group)and 304 were normal women(control group).The baseline parameters including levels of serum follicle-stimulating hormone(FSH),luteinizing hormone(LH),prolactin(PRL),estradiol(E2),testosterone(T)and lipid,as well as the body mass index(BMI)and waist/hip ratio(WHR)were measured.Glucose tolerance and insulin releasing before and after loading with 75 g of glucose were also assayed.Results(1)The frequencies of two allelotypes or three genotypes did not differ between PCOS women and normal women(P＞0.05).(2)In PCOS group,patients with AA genotype had a significantly higher plasma glucose of 180 minutes OGTT(5.7±2.2)mmol/L[P＜0.01 compared to Gagenotype(4.9±1.2) mmol/L,P＜0.01 compared to GG genotype(4.9±1.4)mmol/L]and serum total cholesterol(TC)level(4.9±1.0)mmol/L[P＜0.05 compared to Gagenotype(4.5±0.9)mmol/L].(3)Compared to PCOS patients with GA+GG genotype(P＜0.05,P＜0.01)or GG genotype(P＜0.05,P＜0.01),there was significantly higher attack rate of diabetes and tumor in the family history of patients with AA genotype.Conclusions These findings suggest that CAPN-10 gene SNP-56 which may not contribute to the genetic susceptibility of PCOS plays a role in glucose and lipid metabolism in Chinese PCOS patients.It may also be correlated with attack rate of diabetes and tumor in the family history of PCOS patients.

Objective To determine the expression level of microRNA-25 in animal models of diabetic nephropathy and human renal tubular epithelial cells (HK-2) cultured in different conditions, and to explore its regulating effect on the fibrosis in diabetic nephropathy. Methods The expression of microRNA-25 was detected by real-time PCR. The downstream target protein of microRNA-25 was verified by bioinformatic prediction, transient transfection of cells and Western blotting. Results MicroRNA-25 was down-regulated in animal models of diabetic nephropathy and HK-2 cells which were cultured in high-glucose medium (P<0. 01). MAP2K4 might be the downstream target protein of microRNA-25. Overexpression of microRNA-25 reduced the protein expression of MAP2K4 and α-SMA (P<0. 01). Conclusion MicroRNA-25 inhibits the fibrosis in diabetic nephropathy by regulating the expression of MAP2K4.

Objective To evaluate and compare the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum-resistant ovarian cancer. Methods From January 1,2015 to December 31,2016,80 patients from Hunan Cancer Hospital with recurrent platinum-resistant ovarian cancer were divided into two groups by using random number table method,40 cases in each group:group PLD was treated with liposome doxorubicin and group G/ O was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were evaluated,the expressions of CA125 after treat-ment were compared and the occurrence of adverse reactions were observed. Results The objective response rate(ORR)and disease control rate(DCR)were respectively 27. 5％(11 / 40)and 35. 0％(14 / 40)in group PLD,and the ORR and DCR were respectively 22. 5％(9 / 40)and 27. 5％(11 / 40)in group G/ O,and there was no significant difference between the two groups(χ2 = 0. 27,P = 0. 61;χ2 = 0. 52,P = 0. 47). In PLD group and G/ O group,the CA125 values of ORR patients were(61. 27 ±28. 11)U/ ml and(78. 29 ± 34. 26)U/ ml respectively,with no significant difference(t = 1. 22,P = 0. 24),the CA125 values of non ORR patients were (530. 07 ± 77. 15)U/ ml and(551. 00 ± 78. 78)U/ ml respectively,with no significant difference(t = 1. 04, P = 0. 30). The main adverse reactions in group PLD were hand foot syndrome and myelosuppression. The main adverse reactions in group G/ O were gastrointestinal reaction and myelosuppression. The incidence rates of leucocyte reduction(65. 0％ vs. 92. 5％ ,χ2 = 9. 04,P = 0. 005),thrombopenia(15. 0％ vs. 52. 5％ ,χ2 = 12. 58,P < 0. 001),anemia(15. 0％ vs. 40. 0％ ,χ2 = 6. 27,P = 0. 012),gastrointestinal reaction (17. 5％ vs. 60. 0％ ,χ2 = 15. 22,P < 0. 001)and neurotoxicity(5. 0％ vs. 30. 0％ ,χ2 = 8. 66,P = 0. 006) in group PLD were lower than those in group G/ O,with significant differences. Conclusion The efficacy of two chemotherapy regimens is similar in patients with recurrent platinum-resistant ovarian cancer. Liposome doxorubicin has less adverse reactions than gemcitabine combined with oxaliplatin.